(Q38183312)

30 August 2017

Acute hepatitis C: management in the rapidly evolving world of HCV. (English)

1 reference

30 August 2017

1 reference

1 reference

Suraj A Sharma

1

1 reference

PubMed ID

24477864

30 August 2017

Jordan J Feld

series ordinal

2

1 reference

30 August 2017

1 February 2014

1 reference

Current gastroenterology reports

30 August 2017

1 reference

30 August 2017

16

1 reference

30 August 2017

2

1 reference

30 August 2017

371

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-014-0371-7

30 August 2017

0 references

cites work

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

HCV burden of infection in Egypt: results from a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

General Epidemiological Parameters of Viral Hepatitis A, B, C, and E in Six Regions of China: A Cross-Sectional Study in 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C virus in Pakistan: A systematic review of prevalence, genotypes and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C seroprevalence and associated risk factors, Anyang, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

The changing epidemiology of hepatitis C virus infection in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C virus infection in Eastern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Prevalence of hepatitis C virus and distribution of its genotypes in Northern Eurasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C virus infection in USA: an estimate of true prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Transfusion transmission of HCV, a long but successful road map to safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Dynamics of viremia in early hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Viral and host factors in early hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Interferon signaling in the liver during hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Determinants of viral clearance and persistence during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Natural history of acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C virus-associated fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Case definitions for acute hepatitis C virus infection: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

A short course of pegylated interferon-alpha in acute HCV hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Duration of peginterferon therapy in acute hepatitis C: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-014-0371-7

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection

21 January 2018

1 reference

12 December 2020

Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

1 reference

12 December 2020

Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006

1 reference

12 December 2020

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

1 reference

12 December 2020

Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy

1 reference

12 December 2020

1 reference

12 December 2020

Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012.

1 reference

12 December 2020

Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use.

1 reference

12 December 2020

Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia

1 reference

12 December 2020

Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study

1 reference

12 December 2020

Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

1 reference

12 December 2020

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

1 reference

12 December 2020

10.1007/S11894-014-0371-7

Identifiers

DOI

1 reference

PubMed ID

24477864

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24477864